<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127422">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01443403</url>
  </required_header>
  <id_info>
    <org_study_id>1107V9221</org_study_id>
    <nct_id>NCT01443403</nct_id>
  </id_info>
  <brief_title>A Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of S-297995 for the Treatment of Opioid-Induced Constipation in Subjects With Non-Malignant Chronic Pain Receiving Opioid Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy and safety of S-297995 for the treatment
      of opioid-induced constipation in subjects with non-malignant chronic pain receiving opioid
      therapy for ≥3 months
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average change from baseline in the number of spontaneous bowel movements (SBMs) per week when compared to the average number of SBMs per week during the last 2 weeks of treatment period</measure>
    <time_frame>From randomization to end of treatment period (4 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject global satisfaction</measure>
    <time_frame>From randomization to end of treatment period (4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events, adverse events</measure>
    <time_frame>From randomization to end of study follow-up period (3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential for opioid withdrawal symptoms</measure>
    <time_frame>From randomization to end of study follow-up period (3 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Opioid Induced Constipation</condition>
  <arm_group>
    <arm_group_label>Subjects receiving placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo orally in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving 0.1 mg of S-297995</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive S-297995 and placebo orally in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving 0.2 mg of S-297995</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive S-297995 and placebo orally in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving 0.4 mg of S-297995</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive S-297995 orally in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo once daily</intervention_name>
    <description>Subjects will receive placebo tablets</description>
    <arm_group_label>Subjects receiving placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1 mg of S-297995 once daily</intervention_name>
    <description>Subjects will receive S-297995 tablets and placebo tablets</description>
    <arm_group_label>Subjects receiving 0.1 mg of S-297995</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.2 mg of S-297995 once daily</intervention_name>
    <description>Subjects will receive S-297995 tablets and placebo tablets</description>
    <arm_group_label>Subjects receiving 0.2 mg of S-297995</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.4 mg of S-297995 once daily</intervention_name>
    <description>Subjects will receive S-297995 tablets</description>
    <arm_group_label>Subjects receiving 0.4 mg of S-297995</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 18 years or older at time of informed consent with non-malignant
             chronic pain experiencing opioid-induced constipation

          -  Subjects with &lt;3 spontaneous bowel movements a week and experiencing bowel symptoms

          -  Subjects receiving chronic opioid therapy due to non-malignant pain for ≥3 months

        Exclusion Criteria:

          -  Evidence of clinically significant gastrointestinal disease

          -  History of chronic constipation prior to starting analgesic medication or any
             potential non-opioid cause of bowel dysfunction that may be a major contributor to
             the constipation

          -  Severe constipation that has not been appropriately managed such that the subject is
             at immediate risk of developing serious complications of constipation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 16, 2013</lastchanged_date>
  <firstreceived_date>September 20, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid Therapy</keyword>
  <keyword>Non-Malignant Chronic Pain</keyword>
  <keyword>Opioid-Induced Constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
